Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative a...
适应症为:⑴单药治疗接受过内分泌疗法和化疗后疾病进展的 ER+/HER2-晚期或转移性乳腺癌;⑵或联合氟维司群,二线治疗接受过内分泌疗法后疾病进展的 ER+/HER2-晚期或转移性乳腺癌;⑶联合芳香酶抑制剂作为 ER+/HER2-绝经后女性晚期或转移性乳腺癌的初始内分泌疗法。
BayCare Medical Group, Clearwater, Florida, United States
Texas Oncology-Arlington South, Arlington, Texas, United States
California Cancer Associates Research and Excellence (cCARE), Fresno, California, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Bellevue Hospital Center, New York, New York, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
Rhode Island Hospital, Providence, Rhode Island, United States
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
University of Colorado, Denver, Colorado, United States
OHSU Knight Cancer Institute, Portland, Oregon, United States
UT Southwestern Medical Center - Simmons Comprehensive Cancer Center, Dallas, Texas, United States
Moffitt Cancer Center, Tampa, Florida, United States
Weill Cornell Medicine, New York, New York, United States
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Liverpool Hospital, Liverpool, New South Wales, Australia
North West Cancer Centre, North Tamworth, New South Wales, Australia
St Vincent's Hospital Sydney, Sydney, New South Wales, Australia
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.